Login to Your Account



Exelixis Shares Soar on $1B Cancer Drug Deal with Sanofi

By Donna Young


Friday, May 29, 2009
If all goes according to plan, Exelixis Inc. could bank more than $1 billion under a new licensing and discovery deal with Sanofi-Aventis Group for phosphoinositide-3 kinase (PI3K) inhibitors targeting cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription